The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
Abstract
The 26S proteasome degrades proteins that regulate transcription factor activation, cell cycle progression, and apoptosis. In cancer, this may allow for uncontrolled cell division, promoting tumor growth, and spread. We examined whether selective inhibition of the 26S proteasome with PS‐341, a dipeptide boronic acid analogue, would block proliferation and induce apoptosis in human pancreatic cancer. Proteasome inhibition significantly blocked mitogen (FCS) induced proliferation of BxPC3 human pancreatic cancer cells in vitro, while arresting cell cycle progression and inducing apoptosis by 24 h. Accumulation of p21 Cip1‐Waf‐1, a cyclin dependent kinase (CDK) inhibitor normally degraded by the 26S proteasome, occurred by 3 h and correlated with cell cycle arrest. When BxPC3 pancreatic cancer xenografts were established in athymic nu/nu mice, weekly administration of 1 mg/kg PS‐341 significantly inhibited tumor growth. Both cellular apoptosis and p21 Cip1‐Waf‐1 protein levels were increased in PS‐341 treated xenografts. Inhibition of tumor xenograft growth was greatest (89%) when PS‐341 was combined with the tumoricidal agent CPT‐11. Combined CPT‐11/PS‐341 therapy, but not single agent therapy, yielded highly apoptotic tumors, significantly inhibited tumor cell proliferation, and blocked NF‐κB activation indicating this systemic therapy was effective at the cancer cell level. 26S proteasome inhibition may represent a new therapeutic approach against this highly resistant and lethal malignancy. J. Cell. Biochem. 82: 110–122, 2001. © 2001 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
Statistical Principles in Experimental Design
Myers, J. L., & Winer, B. J. (1964) · The American Journal of Psychology · doi:10.2307/1419292 · Cited by 8,058
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Multiple nuclear factors interact with the immunoglobulin enhancer sequences
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90346-6 · Cited by 2,752
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Cyclin is degraded by the ubiquitin pathway
Glotzer, M., Murray, A. W., & Kirschner, M. W. (1991) · Nature · doi:10.1038/349132a0 · Cited by 2,357
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Self-citationProteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
Apoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Sener, S. F., Fremgen, A., Menck, H. R., & Winchester, D. P. (1999) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(99)00075-7 · Cited by 790
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 472
Self-citationp53-dependent Induction of Apoptosis by Proteasome Inhibitors
Lopes, U. G., Erhardt, P., Yao, R., & Cooper, G. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.12893 · Cited by 467
Wang, Z., Boudjelal, M., Kang, S., Voorhees, J. J., & Fisher, G. J. (1999) · Nature Medicine · doi:10.1038/10577 · Cited by 404
Proteasomes play an essential role in thymocyte apoptosis.
Grimm, L. M., Goldberg, A. L., Poirier, G. G., Schwartz, L. M., & Osborne, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00757.x · Cited by 309
Griscavage, J. M., Wilk, S., & Ignarro, L. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3308 · Cited by 265
Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons.
Sadoul, R., Fernandez, P. A., Quiquerez, A. L., Martinou, I., Maki, M., Schröter, M., Becherer, J. D., Irmler, M., Tschopp, J., & Martinou, J. C. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00758.x · Cited by 260
Lactacystin, a Specific Inhibitor of the Proteasome, Induces Apoptosis in Human Monoblast U937 Cells
Imajohohmi, S., Kawaguchi, T., Sugiyama, S., Tanaka, K., Omura, S., & Kikuchi, H. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2878 · Cited by 206
Cusack, J. C., Liu, R., & Baldwin, A. S. (2000) · PubMed · Cited by 160
NF-κB Activation by Camptothecin
Huang, T. T., Wuerzberger-Davis, S. M., Seufzer, B. J., Shumway, S. D., Kurama, T., Boothman, D. A., & Miyamoto, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9501 · Cited by 159
Rousset, R., Morris, C., Bantignies, F., & Jalinot, P. (1996) · Nature · doi:10.1038/381328a0 · Cited by 137
Sodium Salicylate Activates Caspases and Induces Apoptosis of Myeloid Leukemia Cell Lines
Klampfer, L., Cammenga, J., Wisniewski, H., & Nimer, S. D. (1999) · Blood · doi:10.1182/blood.v93.7.2386 · Cited by 132
Hoffman, E. K., Wilcox, H. M., Scott, R. W., & Siman, R. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00031-7 · Cited by 121
Berlin, J. D., Adak, S., Vaughn, D. J., Flinker, D., Blaszkowsky, L. S., Harris, J. E., & Benson, A. B. (2000) · Oncology · doi:10.1159/000012103 · Cited by 80
Chapter 28. Novel Inhibitors of the Proteasome and Their Therapeutic Use in Inflammation
Adams, J., & Stein, R. L. (1996) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60467-4 · Cited by 66
Self-citationPerugini, R. A., McDade, T. P., Vittimberga, F. J., Duffy, A. J., & Callery, M. P. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80029-3 · Cited by 64
Self-citationGrimm, L. M., & Osborne, B. A. (1999) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69184-6_10 · Cited by 61
Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells
McDade, T. P., Perugini, R. A., Vittimberga, F. J., & Callery, M. P. (1999) · Surgery · doi:10.1016/s0039-6060(99)70179-0 · Cited by 48
Self-citationReduced Survival in Patients With Ductal Pancreatic Adenocarcinoma Associated With CDKN2 Mutation
Bartsch, D. K., Shevlin, D. W., Callery, M. P., Norton, J. A., Wells, S. A., & Goodfellow, P. J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.10.680 · Cited by 34
Self-citationDegradation of tyrosine aminotransferase (TAT) via the ubiquitin–proteasome pathway
Gross-Mesilaty, S., Hargrove, J. L., & Ciechanover, A. J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00181-6 · Cited by 30
Cited by
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationThe proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Self-citationBortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Self-citationNuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Metadata
- Authors
- Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., & Callery, M. P.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2001-06-04
- Volume
- 82
- Issue
- 1
- Pages
- 110-122
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2083308557
- Cited by
- 260
- References
- 39
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.